Provider of gene editing platform for cell and gene therapies for inherited diseases. The company offers the proprietary Exact DNA Integration Technology (EDIT) platform, which is a genome engineering technology that is mammal-derived, for use non-viral gene therapy for patients suffering from inherited diseases and genetic diseases like Familial hypercholesterolemia, and Inherited macular degeneration. The company was founded in 2019 and headquartered in United States. It has raised $152.2M in series b funding, with backing from PBM Capital, GordonMD Global Investments, EPIQ, Fidelity Investments, and others. The company operates in the Life Sciences - Rare Diseases, Life Sciences - Gene Therapy, Life Sciences - Genomics space. Its offerings span Rare Diseases - Drugs - Diversified.
← All startups
SalioGen Therapeutics
Series BProvider of gene editing platform for cell and gene therapies for inherited diseases. The company offers the proprietary Exact DNA Integration Technology (EDIT) platform, which is a genome engineering technology that is mammal-derived, for use non-viral gene therapy for patients suffering from inherited diseases and genetic diseases like Familial hypercholesterolemia, and Inherited macular degeneration. The company…
About
Business model
Rare Diseases > Drugs > Diversified,
Genomics > Enabling Technologies > Technology Platforms > Gene Editing
Institutional investors
PBM CapitalGordonMD Global InvestmentsEPIQFidelity InvestmentsT. Rowe PriceCystic Fibrosis FoundationSymbiosis International UniversityRD FundD1 Capital PartnersSymBiosis
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.
Similar startups
Raising like SalioGen Therapeutics?
Analyze your pitch deck before your next raise.
Analyze My Deck →